Share

Cramer: There will be push back on Biogen's Alzheimer's drug price

The Food and Drug Administration on Monday approved Biogen’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades. CNBC's Jim Cramer, Carl Quintanilla and David Faber discuss.
01:42
Tue, Jun 8 202110:03 AM EDT